Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2062430 · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY2062430 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| LY2062430 | DRUG | 400 mg intravenously (IV) every 4 weeks for 80 weeks |
| Placebo | DRUG | intravenously (IV) every 4 weeks for 80 weeks |
Inclusion Criteria: * Meets criteria for mild to moderate Alzheimer's Disease (AD) with Mini-Mental State Examination score of 16 through 26 at screening * Modified Hachinski Ischemia Scale score of less than or equal to 4 * Geriatric Depression Scale score of less than or equal to 6 * A magnetic r...
Top 20 of 24 competitors
LY2062430 is an investigational small molecule being developed for the treatment of Alzheimer's disease. It has been studied in patients with mild-to-moderate Alzheimer's disease and in healthy volunteers. The drug is currently in Phase 3 clinical development, though all known trials have been completed.
LY2062430 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The company has conducted multiple clinical trials of the drug for Alzheimer's disease.
LY2062430 is in Phase 3 clinical development for Alzheimer's disease. Two Phase 3 trials have been completed, along with one Phase 2 trial. The drug is investigational and has not been approved by regulatory authorities.
LY2062430 has been studied in three completed trials. NCT00329082 was a Phase 2 study in mild-to-moderate Alzheimer's disease and healthy volunteers. NCT00904683 and NCT00905372 were Phase 3 trials evaluating the drug's effect on Alzheimer's disease progression, with enrollments of 1040 and 1000 participants respectively.
LY2062430 is the development code for solanezumab, an investigational monoclonal antibody targeting amyloid beta for Alzheimer's disease. Eli Lilly and Company has studied it in multiple clinical trials, including Phase 3 studies, though it remains investigational.